Omnicell Announces Central Med Automation Service
Omnicell (Nasdaq: OMCL) has unveiled its Central Med Automation Service, a subscription-based solution designed to help health systems optimize centralized medication management. This service integrates enterprise-wide robotics, smart devices, and intelligent software with expert services to streamline medication dispensing from central fulfillment areas throughout health system enterprises.
Key components include the XR2 Automated Central Pharmacy System for advanced medication storage and dispensing, Central Pharmacy Manager software for workflow support, and Inventory Optimization Service for enterprise-wide inventory management. The service also provides ongoing expert guidance, on-site support, and performance tracking to ensure continuous operational optimization.
This solution aims to enhance inventory visibility, scalability, and patient safety while addressing challenges such as drug shortages and staffing issues in pharmacy operations.
Omnicell (Nasdaq: OMCL) ha presentato il suo Central Med Automation Service, una soluzione in abbonamento progettata per aiutare i sistemi sanitari a ottimizzare la gestione centralizzata dei farmaci. Questo servizio integra robotica a livello aziendale, dispositivi intelligenti e software intelligente con servizi esperti per semplificare la distribuzione dei farmaci dalle aree di evasione centrale in tutto il sistema sanitario.
I componenti chiave includono il XR2 Automated Central Pharmacy System per l'archiviazione e la distribuzione avanzate dei farmaci, il software Central Pharmacy Manager per il supporto del flusso di lavoro, e il Inventory Optimization Service per la gestione dell'inventario a livello aziendale. Il servizio fornisce anche orientamento esperto continuo, supporto in loco e monitoraggio delle prestazioni per garantire una continua ottimizzazione operativa.
Questa soluzione mira a migliorare la visibilità dell'inventario, la scalabilità e la sicurezza dei pazienti, affrontando al contempo sfide come la carenza di farmaci e problemi di personale nelle operazioni di farmacia.
Omnicell (Nasdaq: OMCL) ha presentado su Central Med Automation Service, una solución basada en suscripción diseñada para ayudar a los sistemas de salud a optimizar la gestión centralizada de medicamentos. Este servicio integra robótica a nivel empresarial, dispositivos inteligentes y software inteligente con servicios de expertos para agilizar la dispensación de medicamentos desde las áreas de cumplimiento central en todo el sistema de salud.
Los componentes clave incluyen el XR2 Automated Central Pharmacy System para el almacenamiento y la dispensación avanzada de medicamentos, el software Central Pharmacy Manager para el soporte del flujo de trabajo, y el Inventory Optimization Service para la gestión del inventario a nivel empresarial. El servicio también ofrece orientación experta continua, soporte in situ y seguimiento del rendimiento para garantizar una optimización operativa continua.
Esta solución busca mejorar la visibilidad del inventario, la escalabilidad y la seguridad del paciente, al tiempo que aborda desafíos como la escasez de medicamentos y problemas de personal en las operaciones de farmacia.
Omnicell (Nasdaq: OMCL)은 중앙 집중식 약물 관리를 최적화하기 위해 설계된 구독 기반 솔루션인 Central Med Automation Service를 공개했습니다. 이 서비스는 기업 전반의 로봇 공학, 스마트 기기 및 지능형 소프트웨어를 전문 서비스와 통합하여 보건 시스템 내의 중앙 이행 지역에서 약물 분배를 간소화합니다.
주요 구성 요소로는 고급 약물 보관 및 분배를 위한 XR2 Automated Central Pharmacy System, 작업 흐름 지원을 위한 Central Pharmacy Manager 소프트웨어, 그리고 기업 전반의 재고 관리를 위한 Inventory Optimization Service가 포함됩니다. 이 서비스는 또한 지속적인 전문가 지도, 현장 지원 및 성과 추적을 제공하여 지속적인 운영 최적화를 보장합니다.
이 솔루션은 재고 가시성, 확장성, 환자 안전을 향상시키는 것을 목표로 하며, 약물 부족 및 약국 운영의 인력 문제와 같은 과제를 해결합니다.
Omnicell (Nasdaq: OMCL) a dévoilé son Central Med Automation Service, une solution par abonnement conçue pour aider les systèmes de santé à optimiser la gestion centralisée des médicaments. Ce service intègre robotique à l'échelle de l'entreprise, appareils intelligents et logiciels intelligents avec des services d'experts pour rationaliser la distribution des médicaments depuis les zones de préparation centrale dans tout le système de santé.
Les composants clés incluent le XR2 Automated Central Pharmacy System pour le stockage et la distribution avancés des médicaments, le logiciel Central Pharmacy Manager pour le support des flux de travail, et le Inventory Optimization Service pour la gestion des stocks à l'échelle de l'entreprise. Le service fournit également des conseils d'experts continus, un support sur site et un suivi des performances pour assurer une optimisation opérationnelle continue.
Cette solution vise à améliorer la visibilité des stocks, l'évolutivité et la sécurité des patients, tout en s'attaquant à des défis tels que les pénuries de médicaments et les problèmes de personnel dans les opérations de pharmacie.
Omnicell (Nasdaq: OMCL) hat seinen Central Med Automation Service vorgestellt, eine abonnementsbasierte Lösung, die Gesundheitssysteme bei der Optimierung des zentralen Medikationsmanagements unterstützen soll. Dieser Service integriert unternehmensweite Robotik, intelligente Geräte und intelligente Software mit Expertenleistungen, um die Medikamentenausgabe aus zentralen Erfüllungsbereichen in ganzen Gesundheitssystemen zu optimieren.
Wichtige Komponenten sind das XR2 Automated Central Pharmacy System für die fortschrittliche Lagerung und Abgabe von Medikamenten, die Central Pharmacy Manager-Software zur Unterstützung der Arbeitsabläufe und der Inventory Optimization Service für das unternehmensweite Bestandsmanagement. Der Service bietet außerdem kontinuierliche Expertenberatung, Vor-Ort-Unterstützung und Leistungsüberwachung, um eine kontinuierliche betriebliche Optimierung sicherzustellen.
Diese Lösung zielt darauf ab, die Bestandssichtbarkeit, Skalierbarkeit und Patientensicherheit zu verbessern und gleichzeitig Herausforderungen wie Arzneimittelknappheit und Personalprobleme in der Apotheke anzugehen.
- Introduction of a new subscription-based service for centralized medication management
- Integration of robotics, smart devices, and software to streamline medication dispensing
- Potential to enhance inventory visibility, scalability, and patient safety
- Inclusion of ongoing expert services for continuous operational optimization
- Flexibility to support various approaches to centralizing pharmacy operations
- None.
Insights
Omnicell's new Central Med Automation Service represents a strategic move in the healthcare technology sector. This subscription-based solution addresses critical pain points in medication management for health systems, potentially enhancing Omnicell's market position. The service's comprehensive approach, combining robotics, software and expert services, could drive long-term recurring revenue for the company.
However, the impact on Omnicell's financials remains uncertain. The healthcare industry's typically long sales cycles and budget constraints may slow adoption. Additionally, the success of this service will depend on Omnicell's ability to demonstrate clear ROI to health systems, particularly in improving patient safety and operational efficiency.
Investors should monitor adoption rates and customer feedback in the coming quarters to gauge the service's market traction and potential impact on Omnicell's
Omnicell's Central Med Automation Service is a significant innovation in centralized medication management. The integration of XR2 robotics with intelligent software addresses key challenges in pharmacy operations, potentially reducing medication errors and improving inventory management.
The service's scalability is particularly noteworthy, allowing health systems to adapt as they grow. This flexibility could be a major selling point, especially for expanding healthcare networks. The inclusion of continuous on-site support and KPI tracking demonstrates Omnicell's commitment to long-term partnerships, which could lead to higher customer retention.
However, the success of this service will hinge on its ability to seamlessly integrate with existing hospital systems and workflows. Omnicell will need to prove that the service can significantly outperform traditional medication management methods to justify the subscription costs.
Omnicell's new service model aligns with the industry trend towards subscription-based revenue, which could provide more stable and predictable cash flows. This shift from traditional hardware sales to a service-oriented model may improve Omnicell's valuation multiples over time, as investors typically favor recurring revenue streams.
The comprehensive nature of the service, including hardware, software and expert support, could lead to higher average revenue per customer. However, it may also result in longer sales cycles and higher upfront costs for Omnicell.
Investors should focus on metrics such as customer acquisition costs, churn rates and lifetime value of subscribers to assess the long-term profitability of this new business model. The impact on Omnicell's
Full-Service, Scalable Solution Designed to Help Health Systems Establish and Continuously Optimize Centralized Medication Management Operations
Introducing Omnicell Central Med Automation Service, a full-service, scalable solution designed to help health systems establish and continuously optimize centralized medication management operations (Graphic: Business Wire)
“As the health system enterprise grows, we find that traditional methods of medication management can lead to multi-vendor environments that may complicate workflows, often creating unnecessary redundancy and increasing chances for error,” said Randall Lipps, chairman, president, chief executive officer, and founder of Omnicell. “Pharmacy leaders recognize the potential value of centralizing pharmacy services, but often lack the capital budgets, resources, and expertise necessary to transform their infrastructure and scale it over time. Omnicell’s Central Med Automation Service is designed to help health systems develop and execute a central fill strategy while providing the expert support necessary to help ensure this environment meets current and future medication management needs.”
Central Med Automation Service is intended to seamlessly integrate enterprise-wide robotics, smart devices, and intelligent software with expert services in an effort to help health systems establish and continuously optimize their centralized pharmacy operations to support medication management at acute care, remote clinics, and community sites. Central Med Automation Service includes:
Robotics & Smart Devices
XR2 Automated Central Pharmacy System: Advanced medication storage and dispensing robotics are designed to automate critical fulfillment workflows, decrease human error, and maximize inventory control. With
Software
Central Pharmacy Manager for Central Med Automation Service: This intelligent software is specifically designed to support centralized medication management workflows within a CPSC, including medication ordering, receiving, picking, verifying, and restocking. The Central Pharmacy Manager for Central Med Automation Service features enhanced processing power that is meant to handle high medication transaction volumes while streamlining distribution workflows within the central fulfillment environment.
Inventory Optimization Service: A combination of software and expert services, this solution is intended to provide enterprise-wide inventory visibility and management of medication par levels, expiration dates, and usage patterns delivered through data-rich dashboards.
Expert Services
Upfront and Ongoing Guidance: Omnicell experts work with each customer to tailor Central Med Automation Service to a customer’s specific needs, including initial medication storage, distribution, and personnel workflows. Ongoing, data-informed monitoring and updates are intended to ensure continuous operational optimization, efficiency, and patient safety for health system enterprises.
Continuous On-site Support: Dedicated on-site assistance to operate robotics and smart devices is designed to support round-the-clock operational efficiency and productivity.
KPI Performance Tracking: Omnicell expert services utilize data analytics to deliver operational performance metrics, helping to enable informed decision-making and continuous improvement in efficiency.
Several complementary robotics, smart devices, and software tools can be added to extend the capabilities and potential value of Central Med Automation Service. These include Omnicell’s suite of pharmacy carousels and packagers, 340B program management software, and Central Pharmacy Manager Mobile Workstation, a new offering that is designed to untether pharmacy personnel from fixed terminals to accelerate order fulfillment.
“Medications are complex and managing them is even more complex, particularly at a time when we’re challenged with growing drug and pharmacy technician shortages,” said Nilesh Desai, RPh, CPPS, chief pharmacy officer at Baptist Health. “Centralizing pharmacy services helps us address these challenges in an effort to provide better and safer care to our patients and communities. Achieving this vision would not have been possible without business partners like Omnicell who, through Central Med Automation Service, have a stake in the game to make us successful.”
Central Med Automation Service provides the flexibility to support hub and spoke, warehouse, and hybrid approaches to centralizing pharmacy operations, which is intended to help health systems move closer to the industry vision of the Autonomous Pharmacy that seeks to replace manual, error-prone activities with automated processes that are safer and more efficient.
Learn more at omnicell.com/CentralMedAutomationService.
About Omnicell
Since 1992, Omnicell has been committed to transforming pharmacy care through outcomes-centric innovation designed to optimize clinical and business outcomes across all settings of care. Through a comprehensive portfolio of robotics, smart devices, intelligent software, and expert services, Omnicell solutions are helping healthcare facilities worldwide to reduce costs, improve labor efficiency, establish new revenue streams, enhance supply chain control, support compliance, and move closer to the industry vision of the Autonomous Pharmacy. To learn more, visit omnicell.com.
From time to time, Omnicell may use the Company’s investor relations website and other online social media channels, including its Twitter handle www.twitter.com/omnicell, LinkedIn page www.linkedin.com/company/omnicell, and Facebook page www.facebook.com/omnicellinc, to disclose material non-public information and comply with its disclosure obligations under Regulation Fair Disclosure (“Reg FD”).
OMNICELL and the Omnicell logo are registered trademarks of Omnicell, Inc. or one of its subsidiaries.
Forward-Looking Statements
To the extent any statements contained in this press release deal with information that is not historical, these statements are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Without limiting the foregoing, statements including the words “expect,” “intend,” “may,” “will,” “should,” “would,” “could,” “plan,” “potential,” “anticipate,” “believe,” “forecast,” “guidance,” “outlook,” “goals,” “target,” “estimate,” “seek,” “predict,” “project,” and similar expressions are intended to identify forward-looking statements. Forward-looking statements are subject to the occurrence of many events outside Omnicell’s control. Such statements include, but are not limited to, Omnicell’s planned new products and services or developing enhancements to existing products and services, including Central Med Automation Service and the related objectives and expected benefits (and any implied financial impact), and statements about Omnicell’s strategy, plans, objectives, promise and purpose, goals, opportunities, and market or Company outlook. Actual results and other events may differ significantly from those contemplated by forward-looking statements due to numerous factors that involve substantial known and unknown risks and uncertainties. These risks and uncertainties include, among other things, (i) unfavorable general economic and market conditions, including the impact and duration of inflationary pressures, (ii) Omnicell’s ability to take advantage of growth opportunities and develop and commercialize new solutions and enhance existing solutions, (iii) reduction in demand in the capital equipment market or reduction in the demand for or adoption of our solutions, systems, or services, (iv) delays in installations of our medication management solutions or our more complex medication packaging systems, (v) risks related to Omnicell’s investments in new business strategies or initiatives, including its transition to selling more products and services on a subscription basis (vi) risks related to failing to maintain expected service levels when providing our Advanced Services or retaining our Advanced Services customers, (vii) Omnicell’s ability to meet the demands of, or maintain relationships with, its institutional, retail, and specialty pharmacy customers, (viii) continued and increased competition from current and future competitors in the medication management automation solutions market and the medication adherence solutions market, (ix) risks presented by government regulations, legislative changes, fraud and anti-kickback statues, products liability claims, the outcome of legal proceedings, and other legal obligations related to healthcare, privacy, data protection, and information security, including any potential governmental investigations and enforcement actions, litigation, fines and penalties, exposure to indemnification obligations or other liabilities, and adverse publicity as a result of the previously disclosed ransomware incident, (x) any disruption in Omnicell’s information technology systems and breaches of data security or cyber-attacks on its systems or solutions, including the previously disclosed ransomware incident and any potential adverse legal, reputational, and financial effects that may result from it and/or additional cybersecurity incidents, as well as the effectiveness of business continuity plans during any future cybersecurity incidents, countries, (xi) Omnicell’s ability to recruit and retain skilled and motivated personnel, (xii) Omnicell’s ability to protect its intellectual property, (xiii) risks related to the availability and sources of raw materials and components or price fluctuations, shortages, or interruptions of supply, (xiv) Omnicell’s dependence on a limited number of suppliers for certain components, equipment, and raw materials, as well as technologies provided by third-party vendors, and (xv) other risks and uncertainties further described in the “Risk Factors” section of Omnicell’s most recent Annual Report on Form 10-K, as well as in Omnicell’s other reports filed with or furnished to the United States Securities and Exchange Commission (“SEC”), available at www.sec.gov. Forward-looking statements should be considered in light of these risks and uncertainties. Investors and others are cautioned not to place undue reliance on forward-looking statements. All forward-looking statements contained in this press release speak only as of the date of this press release. Omnicell assumes no obligation to update any such statements publicly, or to update the reasons actual results could differ materially from those expressed or implied in any forward-looking statements, whether as a result of changed circumstances, new information, future events, or otherwise, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240820888541/en/
Betsy Martinelli
Director, Corporate Marketing
betsy.martinelli@omnicell.com
Source: Omnicell, Inc.
FAQ
What is Omnicell's new Central Med Automation Service?
What are the key components of Omnicell's Central Med Automation Service?
How does Omnicell's Central Med Automation Service aim to benefit health systems?
What type of support does Omnicell (OMCL) provide with the Central Med Automation Service?
